Proton Radiotherapy for Central Nervous System Tumors

Presented by:
Michael Rutenberg, MD, PhD
Assistant Professor, Department of Radiation Oncology
University of Florida
UF Health Proton Therapy Institute

Faculty Disclosure:

Dr. Rutenberg has disclosed that he has no relevant financial relationships. No one else in a position to control content has any relationships to disclose.

Conflict of interest information for the CME Advisory Committee members can be found on the following website:

Release Date: May 25, 2021
Expiration Date:  May 24, 2022

Target Audience: This course is intended for an audience of specialty physicians, primary care physicians, physician assistants, nurses, as well as others who treat patients with central nervous system tumors.

Learning Objectives:

As a result of participation in this activity, participants should be able to:

  1. Define proton therapy and describe how proton therapy is different from conventional radiation therapy.
  2. Identify and determine how the physical properties of protons may improve outcomes in patients with central nervous system tumors.
  3. Discuss recent clinical study outcomes in neurooncology.

Requirements for successful completion: Certificates are awarded upon successful completion (80% proficiency) of the post-test.

Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resource(s) for further study:

  1. Holtzman, A.L., Rotondo, R.L., Rutenberg, M.S. et al. Proton therapy for skull-base chondrosarcoma, a single-institution outcomes study. J Neurooncol 142, 557–563 (2019).
  2. Dennis ER, Bussiere MR, Niemierko A, et al. A comparison of critical structure dose and toxicity risks in patients with low grade gliomas treated with IMRT versus proton radiation therapy. Technol Cancer Res Treat. 2013;12(1):1-9. doi:10.7785/tcrt.2012.500276
  3. Jalali R, Gupta T, Goda J, Goswami S, et al. Efficacy of Stereotactic Conformal Radiotherapy vs Conventional Radiotherapy on Benign and Low Grade Brain Tumors: A Randomized Clinical Trial. JAMA Oncol. 2017;1;3(10):1368-1376
  4. Rutenberg MS, Rotondo RL, Rao D, et al. Clinical outcomes following proton therapy for adult craniopharyngioma: a single-institution cohort study. J Neurooncol. 2020;147(2):387-395. doi:10.1007/s11060-020-03432-9



For additional information, please contact Christina Mershell at or call (904) 831-4034.


Section # 1449